{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:40Z","timestamp":1707524320229},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,14]]},"DOI":"10.7759\/cureus.16384","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T15:16:28Z","timestamp":1626275788000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug-Eluting Stents: Their Preventative\/Prophylactic Role Against Gemcitabine Induced Acute Coronary Syndrome"],"prefix":"10.7759","author":[{"given":"Jaafar A","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerolos N","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aafreen","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed A","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M","family":"Zakhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiam","family":"Rushdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012481.pub2","article-title":"Drug-eluting stents versus bare-metal stents for acute coronary syndrome","volume":"8","author":"Feinberg J","year":"2017","unstructured":"Feinberg J, Nielsen EE, Greenhalgh J, et al.. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database Syst Rev. 2017, 8:CD012481. 10.1002\/14651858.CD012481.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0410-396","article-title":"Endoplasmic reticulum stress and atherosclerosis","volume":"16","author":"Hotamisligil GS","year":"2010","unstructured":"Hotamisligil GS. Endoplasmic reticulum stress and atherosclerosis. Nat Med. 2010, 16:396-9. 10.1038\/nm0410-396","journal-title":"Nat Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.338673","article-title":"Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation","volume":"287","author":"Oh J","year":"2012","unstructured":"Oh J, Riek AE, Weng S, et al.. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem. 2012, 287:11629-41. 10.1074\/jbc.M111.338673","journal-title":"J Biol Chem"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071667","article-title":"Myocardial reperfusion injury","volume":"357","author":"Yellon DM","year":"2007","unstructured":"Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007, 357:1121-35. 10.1056\/NEJMra071667","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1210816","article-title":"Drug-eluting coronary-artery stents","volume":"368","author":"Stefanini GG","year":"2013","unstructured":"Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013, 368:254-65. 10.1056\/NEJMra1210816","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607991","article-title":"Drug-eluting or bare-metal stents for coronary artery disease","volume":"375","author":"B\u00f8naa KH","year":"2016","unstructured":"B\u00f8naa KH, Mannsverk J, Wiseth R, et al.. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016, 375:1242-52. 10.1056\/NEJMoa1607991","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5b00192","article-title":"Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents","volume":"26","author":"Chen W","year":"2015","unstructured":"Chen W, Habraken TC, Hennink WE, Kok RJ. Polymer-free drug-eluting stents: an overview of coating strategies and comparison with polymer-coated drug-eluting stents. Bioconjug Chem. 2015, 26:1277-88. 10.1021\/acs.bioconjchem.5b00192","journal-title":"Bioconjug Chem"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen K","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012, 60:1581-98. 10.1016\/j.jacc.2012.08.001","journal-title":"J Am Coll Cardiol"},{"key":"ref9","article-title":"Grossman & Baim's cardiac catheterization, angiography, and intervention","author":"Mosucci M","year":"1996","unstructured":"Mosucci M. Grossman & Baim's cardiac catheterization, angiography, and intervention . Lippincott Williams & Wilkins, Philadelphia, USA; 1996."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.09.042","article-title":"Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations","volume":"93","author":"Stankovic G","year":"2004","unstructured":"Stankovic G, Orlic D, Corvaja N, et al.. Incidence, predictors, in-hospital, and late outcomes of coronary artery perforations. Am J Cardiol. 2004, 93:213-6. 10.1016\/j.amjcard.2003.09.042","journal-title":"Am J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/jcecho.jcecho_3_19","article-title":"Vascular damage - coronary artery disease","volume":"30","author":"Cadeddu Dessalvi C","year":"2020","unstructured":"Cadeddu Dessalvi C, Deidda M, Giorgi M, Colonna P. Vascular damage - coronary artery disease. J Cardiovasc Echogr. 2020, 30:S11-6. 10.4103\/jcecho.jcecho_3_19","journal-title":"J Cardiovasc Echogr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.12.023","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron AC","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy. Can J Cardiol. 2016, 32:852-62. 10.1016\/j.cjca.2015.12.023","journal-title":"Can J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17 Suppl 5","author":"Mini E","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006, 17 Suppl 5:v7-12. 10.1093\/annonc\/mdj941","journal-title":"Ann Oncol"},{"key":"ref14","article-title":"Stable ischemic heart disease: indications for revascularization","author":"Levin T","year":"2015","unstructured":"Levin T, Aroesty JM. Stable ischemic heart disease: indications for revascularization. 2015."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher D","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009, 6:e1000097. 10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000163051","article-title":"Gemcitabine-induced acute coronary syndrome: a case report","volume":"18","author":"Ozturk B","year":"2009","unstructured":"Ozturk B, Tacoy G, Coskun U, et al.. Gemcitabine-induced acute coronary syndrome: a case report. Med Princ Pract. 2009, 18:76-80. 10.1159\/000163051","journal-title":"Med Princ Pract"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100325","article-title":"Cardiotoxicity associated with gemcitabine: literature review and a pharmacovigilance study","volume":"13","author":"Hilmi M","year":"2020","unstructured":"Hilmi M, Ederhy S, Waintraub X, et al.. Cardiotoxicity associated with gemcitabine: literature review and a pharmacovigilance study. Pharmaceuticals . 2020, 13:325. 10.3390\/ph13100325","journal-title":"Pharmaceuticals"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/BF03086268","article-title":"Acute chest pain in a patient treated with capecitabine","volume":"17","author":"Camaro C","year":"2009","unstructured":"Camaro C, Danse PW, Bosker HA. Acute chest pain in a patient treated with capecitabine. Neth Heart J. 2009, 17:288-91. 10.1007\/BF03086268","journal-title":"Neth Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2012.42.7.487","article-title":"Acute coronary stent thrombosis in cancer patients: a case series report","volume":"42","author":"Lee JM","year":"2012","unstructured":"Lee JM, Yoon CH. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ J. 2012, 42:487-91. 10.4070\/kcj.2012.42.7.487","journal-title":"Korean Circ J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris HA 3rd","year":"1997","unstructured":"Burris HA 3rd, Moore MJ, Andersen J, et al.. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997, 15:2403-13. 10.1200\/JCO.1997.15.6.2403","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler AB","year":"2000","unstructured":"Sandler AB, Nemunaitis J, Denham C, et al.. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2000, 18:122-30. 10.1200\/JCO.2000.18.1.122","journal-title":"J Clin Oncol"},{"key":"ref22","article-title":"Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine","volume":"48","author":"Heinemann V","year":"1988","unstructured":"Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988, 48:4024-31.","journal-title":"Cancer Res"},{"key":"ref23","article-title":"","volume":"50","author":"Hertel LW","year":"1990","unstructured":"Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res. 1990, 50:4417-22.","journal-title":"Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res"},{"key":"ref24","article-title":"Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides","volume":"50","author":"Gandhi V","year":"1990","unstructured":"Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990, 50:3675-80.","journal-title":"Cancer Res"},{"key":"ref25","article-title":"Action of 2',2'-difluorodeoxycytidine on DNA synthesis","volume":"51","author":"Huang P","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res. 1991, 51:6110-7.","journal-title":"Cancer Res"},{"key":"ref26","article-title":"Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-->5'exonuclease-) fragment","volume":"53","author":"Schy WE","year":"1993","unstructured":"Schy WE, Hertel LW, Kroin JS, Bloom LB, Goodman MF, Richardson FC. Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-->5'exonuclease-) fragment. Cancer Res. 1993, 53:4582-7.","journal-title":"Cancer Res"},{"key":"ref27","article-title":"Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA","volume":"56","author":"Gandhi V","year":"1996","unstructured":"Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996, 56:4453-9.","journal-title":"Cancer Res"},{"key":"ref28","article-title":"Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines","volume":"58","author":"Mackey JR","year":"1998","unstructured":"Mackey JR, Mani RS, Selner M, et al.. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res. 1998, 58:4349-57.","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs181","article-title":"Cancer drugs and the heart: importance and management","volume":"34","author":"Suter TM","year":"2013","unstructured":"Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2013, 34:1102-11. 10.1093\/eurheartj\/ehs181","journal-title":"Eur Heart J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh ET","year":"2004","unstructured":"Yeh ET, Tong AT, Lenihan DJ, et al.. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004, 109:3122-31. 10.1161\/01.CIR.0000133187.74800.B9","journal-title":"Circulation"},{"key":"ref31","unstructured":"GEMZAR (Gemcitabine) package insert. (2014). Accessed. September 28, 2020: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020509s077lbl.pdf."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199803000-00001","article-title":"Gemcitabine--a safety review","volume":"9","author":"Aapro MS","year":"1998","unstructured":"Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anticancer Drugs. 1998, 9:191-201. 10.1097\/00001813-199803000-00001","journal-title":"Anticancer Drugs"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas C","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P, et al.. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008, 134:75-82. 10.1007\/s00432-007-0250-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.144","article-title":"Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants","volume":"2010","author":"Lee AY","year":"2010","unstructured":"Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology Am Soc Hematol Educ Program. 2010, 2010:144-9. 10.1182\/asheducation-2010.1.144","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana AA","year":"2009","unstructured":"Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009, 27:4839-47. 10.1200\/JCO.2009.22.3271","journal-title":"J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2003.10.003","article-title":"The prothrombotic state in cancer: pathogenic mechanisms","volume":"50","author":"De Cicco M","year":"2004","unstructured":"De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004, 50:187-96. 10.1016\/j.critrevonc.2003.10.003","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2459\/01.JCM.0000250874.09273.9b","article-title":"A case of acute myocardial infarction during 5-fluorouracil infusion","volume":"7","author":"Canale ML","year":"2006","unstructured":"Canale ML, Camerini A, Stroppa S, et al.. A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med (Hagerstown). 2006, 7:835-7. 10.2459\/01.JCM.0000250874.09273.9b","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/000331979905001208","article-title":"Acute myocardial infarction following gemcitabine therapy: a case report","volume":"50","author":"Kalapura T","year":"1999","unstructured":"Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy: a case report. Angiology. 1999, 50:1021-5. 10.1177\/000331979905001208","journal-title":"Angiology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/61809-drug-eluting-stents-their-preventativeprophylactic-role-against-gemcitabine-induced-acute-coronary-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:14Z","timestamp":1707507134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/61809-drug-eluting-stents-their-preventativeprophylactic-role-against-gemcitabine-induced-acute-coronary-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.16384","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}